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Abstract This study aimed at determining the causes of
failure of the different proposed strategies to ensure
improvement of medication-overuse headache (MOH)
patients, since they have not been investigated so far,
especially with regard to aspects related to cognitive and
behavioural aspects of symptomatic drugs overused by
them. One hundred and twenty in-patients, 82 females
(68.3 %), median age 49 (42–56) years, affected by MOH
were admitted to the study and treated with abrupt dis-
continuation of the medication overused, a 6-day in-patient
detoxification regimen and an immediate start of person-
alized prophylactic treatment, then followed for 1 year.
Leeds Dependence Questionnaire (LDQ), among all the
clinical variables, was administered at baseline and at
1-year follow-up visit to assess substance dependence. Of
the 120 patients enrolled, 68 (56.7 %) were successfully
detoxified (Responder-group), while 52 (43.3 %) were not
(Non-Responder-group). At baseline, the mean LDQ total
score was slightly higher in the Non-Responder group than
in the Responder group (12.08 ± 2.14 vs. 11.94 ± 1.98).
Although this difference was not significant at baseline
(p [ 0.05), the LDQ total score was significantly different
(p \ 0.001) at the 1-year follow-up visit between the
responder group (7.8 ± 2.3) and the Non-Responder group
(12.1 ± 2.1). Moreover, the pattern of the responses of the
patients in the responder group differed from that of the
Non-Responder-group in the items relating to the com-
pulsion to start, compulsion to continue, primacy of effect,
constancy of state and cognitive set. The results showed
that patients of the Non-Responder group showed a drug
dependence pattern similar to that previously described in
addicts. Conversely, in patients who positively responded
to the procedure, drug-abuse behaviour seemed to be a
consequence of chronic headache, reflecting the need for
daily analgesic use to cope with everyday life.
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Introduction
Medication-overuse headache (MOH) [1] and its treatment
represent the major challenge for a physician in a specialty
headache centre. Its prevalence is 1–1.4 % in the general
population with a peak in women aged 40–50 years (with a
prevalence of 5 % in this subgroup) [1–3], reaching up to
10 % of patients seen in headache clinics [4].
According to the International Classification of Head-
ache Disorders (ICHD-II), MOH implies that headache
is present on C15 days/month with a regular overuse
for [3 months of one or more drugs that can be taken
for acute/symptomatic treatment of headache (C10 days/
month for ergotamine, triptans, opioids, combination
analgesic medications or combination of acute medications
and C15 days/month for analgesics and nonsteroidal anti-
inflammatory drugs—NSAIDs) [5–7].
The detoxification of the patient and the start of a pro-
phylactic therapy is, nowadays, the standard of care all
over the world [8, 9] though there is no established
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consensus concerning withdrawal and detoxification strat-
egies in MOH [10].
Although the majority of patients report an improvement
of headache shortly after withdrawal, long-term studies
(involving follow-up periods of up to 6 years) indicate that
between 24 and 43 % of them relapse (40 % during the
first year after withdrawal) and develop MOH again despite
an initially successful withdrawal therapy [8, 11–14].
Causes of failure of the different proposed regimens
have only partially been investigated [4].
Predictors of relapse in MOH after withdrawal and
detoxification are (1) type of primary headache (migraine
patients had a lower relapse rate than patients with tension-
type headache or a combination of both), (2) type of
overused headache medication (combination of analgesics
with codeine or barbiturates use had the higher rates of
relapse), (3) female gender, (4) long duration of primary
headache, (5) long duration of drug overuse and (6) psy-
chiatric comorbidity [4, 8, 15–17]. In particular, the
impaired control over the use of the substance and pro-
pensity to relapse long after withdrawal symptoms suggest
that a behavioural disorder, such as substance dependence,
play a major role in promoting and maintaining MOH [16].
In the literature, to date, there are clinical, pathophysi-
ological and genetic data supporting a relationship between
MOH and dependence-related behaviour [18]. A deep
knowledge of these aspects can lead to clinical and thera-
peutic implications.
The Leeds Dependence Questionnaire (LDQ) is a self-
completion, 10-item questionnaire, validated to be used in
addiction and psychiatric settings for alcohol and opiate
consumers to measure substance dependence severity
[19, 20].
Some LDQ items were modified by Ferrari et al. [21] so
that they could be applied to consumers of analgesics.
These authors administered the LDQ to three groups of
patients: chronic daily headache (CDH) and episodic
headache groups and a drug addicts group. Interestingly,
similar responses were found in the CDH and the drug
addicted groups. The authors have postulated that CDH
patients have a very strong need for analgesics, which is
similar to the need found in drug addicts. More recently,
the same group administered their modified version of the
LDQ to episodic migraine patients, chronic migraine
patients overusing acute medications and patients suffering
from rheumatic disease [22].
The aim of the present study was to assess cognitive and
behavioural aspects of symptomatic drug overuse in MOH
patients. For this purpose, we administered the LDQ in
MOH patients before and after a detoxification protocol
followed by prophylactic treatment. We aimed to verify if a
different pattern of drug overuse could be identified among
patients which showed improvement as a consequence of
undergoing the treatment protocol compared to those
patients who did not show any improvement.
Patients and methods
Our Institutional Review Board and local Ethical Com-
mittee approved the study and informed consent was
obtained from the participants.
Consecutive new patients underwent a semi-structured,
face-to-face interview in our Headache Centre (Neurologic
Clinic, S.M. Misericordiae Hospital, Perugia, Italy). MOH
diagnosis was made according to ICHD-II modified criteria
[6] by two experienced clinicians of our Headache Centre
based on a semi-structured clinical interview and a
3-month headache diary. Patients with serious concomitant
disease, systemic pathologies, symptomatic headaches, a
current or prior history of drug/alcohol or strong opioid
[23] abuse, pregnant or breastfeeding and aged \18
or [65, were excluded. Included patients were treated with
abrupt discontinuation of the medication overused, a 6-day
in-patient detoxification regimen and an immediate start of
personalized prophylactic treatment and then followed for
1 year.
The standard 6-day in-patient detoxification programme
consisted of (1) verbal advice on abruptly withdrawing the
overused medication, (2) 1,000 cc saline solution hydration
i.v./daily and (3) metoclopramide 10 mg/daily, if needed
[24]. During the in-patient detoxification phase, residual
attacks were treated with a drug not involved in the drug
abuse (an anti-inflammatory drug or a triptan).
Prophylactic drug classes used, chosen according to
individual characteristics (compliance, comorbidities and
tolerability), past experiences of preventive therapies or
kind of their headache, included tricyclic antidepressants,
beta-blockers, antiepileptics, selective serotonin reuptake
inhibitors (SSRIs) and, in some cases, a combination of all
of these. The treatment was maintained for a minimum
period of 3 months. After the baseline visit, they under-
went three intermediate visits (one every 3 months) to
verify prophylactic treatment compliance and side effects,
before the 1-year follow-up visit.
Patients were given a diary to record, on a daily basis,
the occurrence, severity, duration of the headache episodes
and the use of acute medications. Clinical variables
assessed at baseline and at 1-year follow-up included
number of days with headache per month, duration of
headache, pain intensity measured with a 1–100 mm
Visual Analogical Scale (0 = no pain, 100 mm = worst
imaginable pain) and amount and type of abused drugs.
According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV criteria [25], psychiatric
assessment prior to medication withdrawal included a
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semi-structured face-to-face interview for the evaluation of
psychiatric comorbidity with Beck Anxiety Inventory and
Beck Depression Inventory scales to verify the occurrence
of anxiety and depression [26]. Moreover, the Modified
Mini International Neuropsychiatric Interview (M.I.N.I.)
[27] was administered.
The LDQ [19, 21] is composed of 10 items, which are
scored with 4 digits: 0-1-2-3 (0 = never, 1 = sometimes,
2 = often, 3 = nearly always) measuring the severity of
dependence upon substances, independent of the pharma-
cological properties or the quantity of substances overused.
The operational definitions given to the 10 cognitive and
behavioural markers of substance dependence by Raistrick
et al. [19], representing the ICD-10 [20] and DSM-IV [25]
criteria for substance dependence, are pre-occupation,
salience, compulsion to start, planning, maximize effect,
narrowing of repertoire, compulsion to continue, primacy
of effect, constancy of state and cognitive set (items from 1
to 10, respectively). The LDQ total score increases with the
degree of substance dependence, but no cut-off score
indicating dependence has been identified. High LDQ
scores are associated with cognitive preoccupation with
substance use, a compulsion to use, continual use, planning
and organizing future use, maximization of the subjective
experience of substance use, a reduced repertoire of
behaviour with the primacy of substance use and substance
use as an existential coping strategy.
Other details on LDQ have been described previously
[19, 28].
The LDQ was administered at baseline and at 1-year
follow-up visit to assess substance dependence.
Based on clinical outcome at 1 year, two groups were
identified:
• The Responder group (R-group)—Successful detoxifi-
cation: patients with C50 % decrease in headache days/
month from baseline, resolving medication overuse,
within 2 months after detoxification and without
relapse for the following year.
• The Non-Responder group (NR-group)—Unsuccessful
detoxification: patients who returned to a pattern of
medication overuse within 1 year and continued to
complain of a chronic headache.
Specifically, we use the term ‘‘Responder’’ to identify
those patients who responded to the treatment (i.e., an
improvement of headache following detoxification regimen
and prophylactic therapy, reverting chronic headache to an
episodic pattern), as a consequence of treatment adherence,
maintaining abstinence from MOH-inducing medications
in the follow-up period, whereas the term ‘‘Non-Respon-
der’’ refers to the patient group showing no benefits to the
treatment both in terms of reduced headache days and
medication overuse.
Statistical analysis
Statistical analysis was performed using Statistics, Release
6.0. Continuous variables were tested for normality
with Kolmogorov–Smirnov normality test. Comparisons
between groups were made using t test for the majority of
the parameters studied, which followed a normal distribu-
tion. Kruskal–Wallis test was used for age and age of
headache onset variables, which were non-normally dis-
tributed. Categorical variables, shown in the Tables as
percentages, are referred to in the specific column. Per-
centages between groups were compared by the Chi square
test and Fisher’s exact test and p \ 0.05 was chosen as the
minimum level of statistical significance. A two-factor
MANOVA with all LDQ items as dependent variables has
been performed.
Bonferroni adjusted t-values and p values were reported
for post hoc when pairwise-comparisons were performed in
two-way analysis of variance.
Results
A total of 129 patients were consecutively enrolled; 9 of
them were excluded because they failed to appear at fol-
low-up visits.
One-hundred and twenty patients completed the study,
including 82 females (68.3 %), median age 49 (lower–
upper quartiles = 42–56) years. There were no significant
demographic differences between included and excluded
patients. Before detoxification, 59 % of patients overused
more than one type of acute medication.
Details of these 120 MOH patients at baseline are
reported in Tables 1 and 2 display the subtype of acute
treatments abused at baseline.
As shown in Table 1, of the 120 patients included, 68
(56.7 %) were successfully detoxified (R-group). There
were no significant differences between R-group patients
and NR-group patients in age, sex, level of education, age
at headache onset, duration of chronic headache or number
of days with headache per month at baseline. Classes and
doses of drugs overused did not significantly differ between
the R- and NR-groups at baseline.
The drugs used for prophylactic treatment after detoxi-
fication by patients in the R- and NR-groups are reported in
Table 3. The use of antidepressants was more significantly
higher in the R-group (v2 = 4.10, p = 0.0427), whereas
antiepileptics (v2 = 3.97, p = 0.0462) were the drugs
more often used by patients in the NR-group. No statisti-
cally significant differences were found in other prophy-
lactic treatments and also for combination of prophylactic
treatments, between the two groups. Duration of prophy-
lactic treatment ranged from 9 months to 1 year in the
J Headache Pain (2012) 13:653–660 655
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Table 1 Clinical details of MOH patients at baseline
Total group R-group NR-group Test statistics p-value









v2 ¼ 0:95 0.3286
Age (years) 49 (42–56) 50.5 (44–55) 50 (39–54) v2 ¼ 1:22 0.2690
Marital status
Married 67 (55.8 %) 37 (54.4 %) 30 (57.7 %) v2 ¼ 0:44 0.9312
Unmarried 39 (32.5 %) 22 (32.4 %) 17 (32.7 %)
Divorced 11 (9.2 %) 7 (10.3 %) 4 (7.7 %)
Widowed 3 (2.5 %) 2 (2.9 %) 1 (1.9 %)
Education
Primary school 21 (17.5 %) 12 (17.6 %) 9 (17.3 %) v2 ¼ 0:36 0.9484
Secondary school 38 (31.7 %) 22 (32.4 %) 16 (30.8 %)
High school 37 (30.8 %) 20 (29.4 %) 17 (32.7 %)
University degree 24 (20.0 %) 14 (20.6 %) 10 (19.2 %)
Age at headache onset (years) 24 (19–26.5) 23.5 (18–26.5) 24 (19–26.5) t = 1.46 0.1381
Duration of chronic pain (years) 16.4 ± 4.4 15.9 ± 4.2 17.1 ± 4.6 t = 1.55 0.1252
Number of days with pain/month 23.6 ± 4.7 22.9 ± 4.3 24.3 ± 5.1 t = 1.18 0.2397
VAS score 77.6 ± 20.8 78.5 ± 19.9 76.7 ± 21.7 t = 1.19 0.2659
Continuous variables are expressed as mean ± SD, except for age and age at headache onset (median and interquartile range). For age and age of
headache onset variables Kruskal–Wallis test was used and relative Chi square values are reported. For the other continuous variable t test was
used. Percentages between groups were compared by the Chi square test
Table 2 Overused drugs by MOH patients at baseline
Total (n = 120) R-group (n = 68) NR-group (n = 52) Test statistics p value
Simple analgesics/NSAIDs
Acetaminophen 27 (22.5 %) 13 (19.1 %) 14 (26.9 %) v2 ¼ 1:03 0.3103
Diclofenac 32 (26.7 %) 15 (22.1 %) 17 (32.7 %) v2 ¼ 1:70 0.1918
Ketorolac 11 (9.2 %) 6 (8.8 %) 5 (9.6 %) v2 ¼ 0:02 0.8816
Naproxen 18 (15.0 %) 10 (14.7 %) 8 (15.4 %) v2 ¼ 0:01 0.9178
Nimesulide 16 (13.3 %) 9 (13.2 %) 7 (13.5 %) v2 ¼ 0:00 0.9712
Piroxicam 13 (10.8 %) 6 (8.2 %) 7 (13.5 %) v2 ¼ 0:66 0.4179
Tramadol 15 (12.5 %) 8 (11.8 %) 7 (13.5 %) v2 ¼ 0:08 0.7806
Combination analgesics
Butalbital ? propyphenazone ? caffeine 21 (17.5 %) 11 (16.2 %) 10 (19.2 %) v2 ¼ 0:19 0.6626
Indomethacin ? prochlorperazine ? caffeine 24 (20.0 %) 11 (16.2 %) 13 (25.0 %) v2 ¼ 1:43 0.2311
Opioid analgesics
Acetaminophen ? codeine 6 (5.0 %) 3 (4.4 %) 3 (5.8 %) v2 ¼ 0:11 0.7353
Triptans
Sumatriptan 8 (6.7 %) 5 (7.4 %) 3 (5.8 %) v2 ¼ 0:11 0.7304
Zolmitriptan 7 (5.8 %) 3 (4.4 %) 4 (7.7 %) v2 ¼ 0:58 0.4474
Rizatriptan 12 (10.0 %) 6 (8.8 %) 6 (11.5 %) v2 ¼ 0:24 0.6232
Eletriptan 11 (9.2 %) 6 (8.8 %) 5 (9.6 %) v2 ¼ 0:02 0.8816
Frovatriptan 9 (7.5 %) 4 (5.9 %) 5 (9.6 %) v2 ¼ 0:59 0.4417
The sum of the percentages exceeds 100 % because the majority of patients used more than one simple analgesic. Patients with overuse of a
combination of acute medications: n = 38 (31.7 %)
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majority of patients (90.8 %) who completed the study and,
at 1-year follow-up visit, 101/120 patients (51 in the
R-group and 50 in the NR-group) were still under pro-
phylactic treatment. At follow-up, 17 patients in the
R-group had discontinued prophylactic treatment (tricyclic
antidepressants: n = 5, antiepileptics: n = 4, beta-block-
ers: n = 2, SSRIs: n = 2, combination of prophylactic
treatment: n = 4), whereas only 2 patients in the NR-group
discontinued treatment (tricyclic antidepressants: n = 1,
beta-blockers: n = 1).
Two-way analysis of variance was performed for fre-
quency of headache and headache score with Responder/
Non-Responder as a between-subjects factor and time
(baseline vs. follow-up) as a within-subjects factor. The
Responder/Non-Responder 9 Time interaction effect was
significant for both in frequency of headache (F = 143.49,
p \ 0.001) and in headache score (F = 150.9, p \ 0.001).
Significant results were found in post hoc analysis. Com-
parison between baseline and 1-year follow-up in the
R- and NR-groups showed a statistically significant decrease
in frequency of headache in the R-group (23.53 ± 3.50 vs.
11.31 ± 5.26 days with headache/month, t = 18.42,
p \ 0.001) while in the NR-group there was no significant
difference (24.23 ± 2.99 vs. 24.08 ± 2.79 days with head-
ache/month, t = 0.20, p = 1.000).
VAS scores measured at 1 year was 32.4 ± 12.9 in the
R-group and 69.7 ± 21.7 in the NR-group (t = 19.64,
p \ 0.01).
Unfortunately, patients with \50 % decrease in head-
ache frequency (all belonging to NR-group) continued to
overuse symptomatic medications.
Both groups had the same percentage of aggregated
categories of all mood disorders and all anxiety disorders.
A similar percentage distribution was found at baseline for
individual disorders, including current major depressive
episodes, generalized anxiety disorder, panic disorder with
or without agoraphobia and current social phobias
(Table 4).
Mean Beck Depression Inventory scores did not differ
significantly between R- and NR-groups at the baseline
(21.6 ± 11.4 vs. 22.5 ± 10.9, t = 1.18, p = 0.238) as well
as for the Beck Anxiety Inventory scores (22.1 ± 11.3 vs.
23.6 ± 10.8, t = 1.18, p = 0.238).
At baseline, the mean LDQ total score was slightly
higher in the NR-group than in the R-group (12.1 ± 2.1 vs.
11.9 ± 2.0 LDQ total score, t = 0.35, p = 1.000).
Although this difference was not significant at baseline, the
LDQ total score was significantly higher in the NR-group
than in the R-group at 1-year follow-up (12.1 ± 2.1 vs.
7.8 ± 2.3 LDQ total score, t = 0.35, p \ 0.001). A two-
factor MANOVA with all LDQ items as dependent
variables has been performed. The overall effects are
significant with respect of R/NR-groups (F = 15.92,
p \ 0.001), baseline/follow-up (F = 7.73, p \ 0.001), the
interaction between R/NR groups and baseline/follow-up
(F = 7.21, p \ 0.001).
As shown in Table 5, a statistically significant differ-
ence, between the pattern of the responses of the patients in
the R-group and that of the NR-group, was found in items
3, 7, 8, 9 and 10. In particular, R-group patients, in items 3
and 9, had significantly lower scores than NR-group
patients at both baseline and 1-year follow-up. R-group
patients, in item 7, had significantly lower scores than
NR-group patients at 1-year follow-up. Furthermore, at 1-year
follow-up, R-group patients had significantly lower scores
than baseline and NR-group patients in items 8 and 10.
Discussion
In the present study, we used the LDQ to assess cognitive
and behavioural features of substance dependence in a
group of MOH patients attending our headache centre. A
different pattern of responses was observed between MOH
patients who continued to overuse symptomatic medica-
tions and therefore retained a chronic pattern of headache
(NR-group) and those patients who showed an improve-
ment C50 % in headache days/month from baseline, not
overusing symptomatic drugs and without any relapse at
1-year follow-up (R-group).
Although the LDQ total score at baseline was not sta-
tistically different between the R- and the NR-groups,
specific items were statistically significant. The NR-group
had the highest subscores for items 3 and 9, which mea-
sure, respectively, the inability to refrain from using a
substance and the need to continue its administration to











Tricyclic antidepressants 24 (20.0 %) 18 (26.5 %) 6 (11.5 %) v2 ¼ 4:10 0.0427
Beta-blockers 7 (5.8 %) 4 (5.9 %) 3 (5.8 %) v2 ¼ 0:00 0.9791
Antiepileptics 50 (41.7 %) 23 (33.8 %) 27 (54.0 %) v2 ¼ 3:97 0.0462
SSRIs 5 (4.2 %) 5 (7.3 %) 0 (0 %) v2 ¼ 3:99 0.0683
Combination of prophylactic
treatments
29 (24.2 %) 14 (20.6 %) 15 (28.8 %) v2 ¼ 1:09 0.2950
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maintain well-being, therefore fulfilling DSM-IV criteria
[25] for dependency. Indeed, item 3 investigates the com-
pulsion to start to take drugs, which concerns a persistent
desire or failure to cut-down on substance use, whereas
item 9 measures the constancy of state, investigating the
need to maintain a constant drug effect.
At 1-year follow-up, the LDQ total score was statisti-
cally lower in the R-group than in the NR-group, which
means that this type of psychometric testing can carefully
assess the pathological substance use as well as the treat-
ment efficacy. Specifically, the R-group, compared with the
NR-group at 1-year follow-up, no longer showed the need
to organize their day around obtaining and using the sub-
stance, or continue using the substance in order to enhance
or prolong the state achieved by initial use, as shown by
statistically lower subscores for items 4, 6, 7 and 8. Par-
ticularly, item 8 investigates the primacy of effect, indi-
cating that any pharmacological effect obtained by the used
drug was more important than the resolution of a specific
problem.
Furthermore, the R-group showed a statistically higher
subscore at baseline compared with the NR-group for item
10. This subscore drastically fell at 1-year follow-up in
R-group but did not significantly vary in NR-group at
1 year. Item 10 assesses the cognitive set, 1concerning that
drug use is needed to cope with everyday life and without
its intake the person’s existence might not be possible.
Therefore we can postulate that, patients in R-group
consider the abused drugs to overcome chronic head pain
and necessary to return to a normal functioning. This might
indicate a different perception of the overused painkillers
among the two groups: in the responder one the perception
changed to positive when an improvement of headache is
achieved with an adequate headache management; other-
wise, it is not modified in Non-Responder patients.
Therefore, in our study, patients with unsuccessful out-
come (NR-group) had, in some items, a LDQ subscore
similar to that found in addicts in items assessing
compulsive dependence according to DSM-IV criteria
[18, 25, 29].







Test statistics p value
Major depressive episode n (%) 15 (12.5 %) 9 (13.2 %) 6 (11.5 %) v2 ¼ 0:08 0.7806
All mood disorders n (%) 75 (62.5 %) 43 (63.2 %) 32 (61.5 %) v2 ¼ 0:04 0.8491
Generalized anxiety disorder n (%) 29 (24.2 %) 16 (23.5 %) 13 (25.0 %) v2 ¼ 0:03 0.8521
Panic disorder n (%) 19 (15.8 %) 10 (14.7 %) 9 (17.3 %) v2 ¼ 0:15 0.6988
Social phobia n (%) 27 (22.5 %) 15 (22.1 %) 12 (23.1 %) v2 ¼ 0:02 0.8947
All anxiety disorders n (%) 58 (48.3 %) 33 (48.5 %) 25 (48.1 %) v2 ¼ 0:00 0.9608
The sum of the percentages exceeds 100 % because some patients had more than one psychiatric disorder
Table 5 Leeds Dependence Questionnaire (LDQ) score (mean ± SD) for the R-group and the NR-group at baseline and at 1-year follow-up
Item R-group NR-group
Baseline 1 year Baseline 1 year
1. Do you find yourself thinking about when you will next be able to take analgesics? 1.4 ± 0.8 1.0 ± 0.6* 1.3 ± 0.9 1.3 ± 0.9
2. Is taking analgesics more important than anything else you might do during the day? 0.8 ± 0.7 0.7 ± 0.6 1.0 ± 0.7 0.9 ± 0.6
3. Do you feel your need for analgesics is too strong to control? 0.9 ± 0.8 0.6 ± 0.6 1.3 ± 0.7 1.4 ± 0.6
4. Do you plan your days around taking analgesics? 0.9 ± 0.5 0.6 ± 0.5 1.0 ± 0.7 1.0 ± 0.7
5. Do you take analgesics in a particular way in order to increase the effect it gives
you?
0.7 ± 0.7 0.6 ± 0.6 0.7 ± 0.7 0.7 ± 0.7
6. Do you take analgesics morning, afternoon and evening? 1.4 ± 0.5 1.0 ± 0.5**, 1.5 ± 0.5 1.5 ± 0.5
7. Do you feel you have to continue taking analgesics once you have started? 1.0 ± 0.7 0.8 ± 0.6 1.3 ± 0.6 1.3 ± 0.6
8. Is getting the effect you want more important than the particular analgesic you use? 2.1 ± 0.6 1.0 ± 0.7**, 1.8 ± 0.7 1.8 ± 0.7
9. Do you want to take more analgesics when the effect starts to wear off? 0.9 ± 06 0.7 ± 0.5 1.6 ± 0.7 1.5 ± 0.7
10. Do you find it difficult to cope with life without analgesics? 1.9 ± 0.7 1.1 ± 0.6** 1.3 ± 0.7 1.2 ± 0.6
LDQ total score 11.9 ± 2.0 7.8 ± 2.3**, 12.8 ± 2.1 12.1 ± 2.1
Differences within each group at baseline and at 1-year follow-up: * p B 0.01, ** p \ 0.001
Differences between the R- and NR-groups at baseline and at 1-year follow-up: p B 0.007, p \ 0.001
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Conversely, in R-group patients, drug-dependence
behaviour seemed to be more a consequence of the chronic
headache, reflecting the need for daily analgesic use to
cope with everyday life; their LDQ scores at 1-year follow-
up were similar to those found in episodic migraine in a
previous study [21].
Based on the above results, we believe that there are two
different subgroups in MOH patients: those with a sub-
stance abuse as the persistence of adverse social, psycho-
logical or medical consequences related to the repeated use
of substances and who were responders to treatment, and
those with substance dependence, identified by physiolog-
ical markers of withdrawal and tolerance effects and who
were Non-Responders to the treatment, leading to the
resumption of medication and seemed to have a depen-
dence behaviour similar to that of a drug addict.
In these NR-group patients, mechanisms underlying
sensitization could be more similar to those described for
other forms of drug addiction [18].
Moreover, cognitive impulsivity in drug overuse
patients seems more strictly associated with dysfunction of
the fronto-striatal system resembling the compulsive
reward-seeking of addicts [30]. These peculiar aspects
could explain the difficulty in avoiding overuse substances
and the low compliance of these patients.
The different prophylactic treatments used by MOH
patients might have some influence on the results. In fact,
in the R-group the use of antidepressant drugs was higher
than in the NR-group. Interestingly, most of the antide-
pressant drugs influence the striato-thalamo-orbitofrontal
circuit [31], that is also involved in the pathogenesis of
MOH and drug-seeking behaviour [30, 32–37].
Behavioural correlates of some MOH patients might in
part resemble some of the characteristics of the behavioural
sensitisation to psycho-stimulants [16, 18, 38]. Among
these characteristics, the most important are the need to
repetitively take drugs during a certain period of time and
the occurrence of cross-sensitisation among different drugs
used to treat headache. In addition, in these subjects, the
possibility of a relapse after relatively long periods of
abstinence suggests a vulnerability to drug dependence
[39, 40]. This seems to be the prevailing mechanism
underlying the inefficacy of the detoxification regimen and
prophylactic treatment in the NR-group.
The distinguishing factor of the present study from past
studies is the use of the LDQ to better characterize the
patients with MOH and to find some dependence traits
which have an impact on treatment regimen. For this rea-
son, it is our opinion that MOH patients need an integrated
treatment programme that should aim to address both
substance abuse and dependence in parallel. This recom-
mendation necessitates the accurate clinical assessment of
substance dependence in this population.
In particular, the LDQ subscores can be useful to verify
the pattern of dependence in patients with MOH which
could be different between patients satisfactorily respond-
ing to the treatment and those who do not.
This study has some limits which need to be addressed:
LDQ has not yet been validated for the analgesics depen-
dence and thus further validity studies are required. Sen-
sitivity and specificity of each LDQ items in predicting the
outcome of the MOH patients should be investigated;
furthermore, patients were evaluated neither for other risk
factors for relapse to drug overuse nor for other comor-
bidities, especially for other chronic painful disorders
overusing analgesics (such as fibromyalgia, low back pain
or neuropathic pain). These aspects should be fully clarified
in future research.
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